Case Report: Heparin-induced thrombocytopenia in a patient with COVID-19.
Ragia AlySachin GuptaSorab GuptaBalraj SinghAbhinav GoyalSheila KalathilPublished in: F1000Research (2020)
With the spread of the novel coronavirus disease of 2019 (COVID-19) worldwide and associated high incidence of thromboembolic complications, the use of heparin is on the rise. It therefore is crucial to identify patients with contraindications for heparin. Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of exposure to heparin. We report a 66-year-old woman, who was admitted to the hospital with COVID-19 infection. Her course was complicated by pulmonary embolism and dialysis catheter thrombosis. Our patient had a known history of HIT. Treatment of this patient with heparin would have been catastrophic. The COVID-19 pandemic has overwhelmed healthcare systems and is causing a global health crisis. Nevertheless, this case serves as a reminder of the importance of making every effort to obtain thorough history and review of records of every patient.
Keyphrases
- case report
- coronavirus disease
- pulmonary embolism
- venous thromboembolism
- growth factor
- healthcare
- global health
- sars cov
- public health
- risk factors
- high glucose
- inferior vena cava
- diabetic rats
- chronic kidney disease
- emergency department
- oxidative stress
- adverse drug
- endothelial cells
- end stage renal disease
- peritoneal dialysis
- ultrasound guided
- electronic health record
- affordable care act